Brief: Diamedica Therapeutics Announces Positive Interim Results From Phase 2 Redux Study In Ckd

DiaMedica Therapeutics

29/06/2021 12:02

June 29 (Reuters) - DiaMedica Therapeutics Inc  DMAC.O :
    * DIAMEDICA THERAPEUTICS ANNOUNCES POSITIVE INTERIM RESULTS
FROM
PHASE 2 REDUX STUDY IN CKD
    * DIAMEDICA THERAPEUTICS INC - RESULTS AFFIRM BIOLOGICAL
ACTIVITY,
SAFETY AND TOLERABILITY OF DM199 CONSISTENT WITH PORCINE KLK1
PRODUCT IN ASIA
    * DIAMEDICA - EARLY DATA INDICATE STATISTICALLY AND
CLINICALLY
SIGNIFICANT REDUCTION IN UACR SEEN IN IGA NEPHROPATHY AND
HYPERTENSIVE AFRICAN AMERICANS
    * DIAMEDICA THERAPEUTICS INC - STUDY DEMONSTRATES STABLE
EGFR AND
POSITIVE EFFECTS ON BLOOD PRESSURE ACROSS ALL COHORTS
    * DIAMEDICA THERAPEUTICS INC - DM199 WAS WELL TOLERATED
ACROSS ALL
COHORTS, WITH NO DM199 RELATED SEVERE ADVERSE EVENTS

Source text for Eikon:  ID:nBw836jVwa 
Further company coverage:  DMAC.O 

 ((Reuters.Briefs@thomsonreuters.com;))